Serum sclerostin in vascular calcification and clinical outcome in chronic kidney disease

Cong Zeng, Chunyuan Guo, Juan Cai, Chengyuan Tang, Zheng Dong

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Sclerostin, a potent soluble inhibitor of the Wnt signalling pathway, is known to inhibit bone formation by suppressing osteocytes differentiation and function. Patients with chronic kidney disease have high levels of serum sclerostin. Sclerostin has been implicated in the pathogenesis of vascular calcification, which may promote the cardiovascular events of morbidity and mortality in chronic kidney disease patients. However, the role of sclerostin in vascular calcification and clinical prognosis in chronic kidney disease remains elusive. While some studies suggested a positive correlation between serum sclerostin and vascular calcification or clinical outcome, other studies showed no or even negative correlation between them. Small sample size, heterogeneity in enrolled patients, discrepancy in anatomical structure examined and differences in the applied assays may be responsible for the discrepant results. Nonetheless, anti-sclerostin antibodies may be a new therapeutic approach to increase bone mass and strength in chronic kidney disease. This review aims to have a better understanding of the relationship of serum sclerostin with vascular calcification and clinical outcome in chronic kidney disease patients, and propose the application of anti-sclerostin therapy in chronic kidney disease.

Original languageEnglish (US)
Pages (from-to)99-105
Number of pages7
JournalDiabetes and Vascular Disease Research
Volume15
Issue number2
DOIs
StatePublished - Mar 1 2018

Fingerprint

Vascular Calcification
Chronic Renal Insufficiency
Serum
Osteocytes
Wnt Signaling Pathway
Osteogenesis
Sample Size
Anti-Idiotypic Antibodies
Outcome Assessment (Health Care)
Morbidity
Bone and Bones
Mortality
Therapeutics

Keywords

  • Chronic kidney disease
  • Wnt
  • sclerostin
  • vascular calcification

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Cite this

Serum sclerostin in vascular calcification and clinical outcome in chronic kidney disease. / Zeng, Cong; Guo, Chunyuan; Cai, Juan; Tang, Chengyuan; Dong, Zheng.

In: Diabetes and Vascular Disease Research, Vol. 15, No. 2, 01.03.2018, p. 99-105.

Research output: Contribution to journalReview article

Zeng, Cong ; Guo, Chunyuan ; Cai, Juan ; Tang, Chengyuan ; Dong, Zheng. / Serum sclerostin in vascular calcification and clinical outcome in chronic kidney disease. In: Diabetes and Vascular Disease Research. 2018 ; Vol. 15, No. 2. pp. 99-105.
@article{0bc256f9492c4f48afc3c8a90fb66d1b,
title = "Serum sclerostin in vascular calcification and clinical outcome in chronic kidney disease",
abstract = "Sclerostin, a potent soluble inhibitor of the Wnt signalling pathway, is known to inhibit bone formation by suppressing osteocytes differentiation and function. Patients with chronic kidney disease have high levels of serum sclerostin. Sclerostin has been implicated in the pathogenesis of vascular calcification, which may promote the cardiovascular events of morbidity and mortality in chronic kidney disease patients. However, the role of sclerostin in vascular calcification and clinical prognosis in chronic kidney disease remains elusive. While some studies suggested a positive correlation between serum sclerostin and vascular calcification or clinical outcome, other studies showed no or even negative correlation between them. Small sample size, heterogeneity in enrolled patients, discrepancy in anatomical structure examined and differences in the applied assays may be responsible for the discrepant results. Nonetheless, anti-sclerostin antibodies may be a new therapeutic approach to increase bone mass and strength in chronic kidney disease. This review aims to have a better understanding of the relationship of serum sclerostin with vascular calcification and clinical outcome in chronic kidney disease patients, and propose the application of anti-sclerostin therapy in chronic kidney disease.",
keywords = "Chronic kidney disease, Wnt, sclerostin, vascular calcification",
author = "Cong Zeng and Chunyuan Guo and Juan Cai and Chengyuan Tang and Zheng Dong",
year = "2018",
month = "3",
day = "1",
doi = "10.1177/1479164117742316",
language = "English (US)",
volume = "15",
pages = "99--105",
journal = "Diabetes and Vascular Disease Research",
issn = "1479-1641",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Serum sclerostin in vascular calcification and clinical outcome in chronic kidney disease

AU - Zeng, Cong

AU - Guo, Chunyuan

AU - Cai, Juan

AU - Tang, Chengyuan

AU - Dong, Zheng

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Sclerostin, a potent soluble inhibitor of the Wnt signalling pathway, is known to inhibit bone formation by suppressing osteocytes differentiation and function. Patients with chronic kidney disease have high levels of serum sclerostin. Sclerostin has been implicated in the pathogenesis of vascular calcification, which may promote the cardiovascular events of morbidity and mortality in chronic kidney disease patients. However, the role of sclerostin in vascular calcification and clinical prognosis in chronic kidney disease remains elusive. While some studies suggested a positive correlation between serum sclerostin and vascular calcification or clinical outcome, other studies showed no or even negative correlation between them. Small sample size, heterogeneity in enrolled patients, discrepancy in anatomical structure examined and differences in the applied assays may be responsible for the discrepant results. Nonetheless, anti-sclerostin antibodies may be a new therapeutic approach to increase bone mass and strength in chronic kidney disease. This review aims to have a better understanding of the relationship of serum sclerostin with vascular calcification and clinical outcome in chronic kidney disease patients, and propose the application of anti-sclerostin therapy in chronic kidney disease.

AB - Sclerostin, a potent soluble inhibitor of the Wnt signalling pathway, is known to inhibit bone formation by suppressing osteocytes differentiation and function. Patients with chronic kidney disease have high levels of serum sclerostin. Sclerostin has been implicated in the pathogenesis of vascular calcification, which may promote the cardiovascular events of morbidity and mortality in chronic kidney disease patients. However, the role of sclerostin in vascular calcification and clinical prognosis in chronic kidney disease remains elusive. While some studies suggested a positive correlation between serum sclerostin and vascular calcification or clinical outcome, other studies showed no or even negative correlation between them. Small sample size, heterogeneity in enrolled patients, discrepancy in anatomical structure examined and differences in the applied assays may be responsible for the discrepant results. Nonetheless, anti-sclerostin antibodies may be a new therapeutic approach to increase bone mass and strength in chronic kidney disease. This review aims to have a better understanding of the relationship of serum sclerostin with vascular calcification and clinical outcome in chronic kidney disease patients, and propose the application of anti-sclerostin therapy in chronic kidney disease.

KW - Chronic kidney disease

KW - Wnt

KW - sclerostin

KW - vascular calcification

UR - http://www.scopus.com/inward/record.url?scp=85042286971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042286971&partnerID=8YFLogxK

U2 - 10.1177/1479164117742316

DO - 10.1177/1479164117742316

M3 - Review article

C2 - 29168393

AN - SCOPUS:85042286971

VL - 15

SP - 99

EP - 105

JO - Diabetes and Vascular Disease Research

JF - Diabetes and Vascular Disease Research

SN - 1479-1641

IS - 2

ER -